Please ensure Javascript is enabled for purposes of website accessibility

Are Cardiac Device Stocks About to Boom?

By Dan Carroll – Jan 25, 2014 at 11:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In the wake of St. Jude Medical's recent earnings release, we check in on what you need to watch at Medtronic and Boston Scientific.

Medical device companies have been under pressure lately, but you wouldn't know it by looking at their stocks. Leading cardiac device makers such as Boston Scientific (BSX 0.23%) and St. Jude Medical (STJ) have seen their stocks explode behind the market's rally recently, making investors wealthy and igniting hope for more as these companies look to turn around sluggish sales.

St. Jude recently reported its own earnings for the fourth quarter, topping analyst expectations on both its top and bottom lines. Despite the struggles of the cardiac rhythm management industry as of late in slowing sales for devices such as defibrillators, St. Jude's turning the corner in seeing revenue rise once again.

Will St. Jude's successful quarter rub off on fellow cardiovascular leaders Boston Scientific and Medtronic (MDT 0.34%) in their own upcoming quarterly earnings reports? In the video below, Motley Fool contributor Dan Carroll takes you through how St. Jude's bouncing back from the device industry's post-recession downturn -- and how industry trends are pointing in the right direction for top device stocks in the long term. 

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.